Vicarious Surgical (NYSE:RBOT) Lowered to “Sell” Rating by Wall Street Zen

Vicarious Surgical (NYSE:RBOT) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other research analysts have also recently issued reports on the stock. BTIG Research reiterated a “neutral” rating on shares of Vicarious Surgical in a research note on Friday, December 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Vicarious Surgical in a research report on Wednesday, January 21st. Two equities research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vicarious Surgical presently has a consensus rating of “Reduce” and an average target price of $7.00.

Vicarious Surgical Stock Performance

Shares of NYSE:RBOT opened at $2.21 on Friday. Vicarious Surgical has a 52 week low of $1.80 and a 52 week high of $16.35. The company’s fifty day moving average is $2.50 and its 200-day moving average is $5.18. The company has a market capitalization of $14.48 million, a PE ratio of -0.24 and a beta of 1.52.

Vicarious Surgical (NYSE:RBOT) last announced its earnings results on Wednesday, November 12th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.37) by $0.46. On average, analysts forecast that Vicarious Surgical will post -10.89 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RBOT. Connective Capital Management LLC acquired a new stake in shares of Vicarious Surgical in the 3rd quarter valued at $169,000. Dimensional Fund Advisors LP boosted its holdings in Vicarious Surgical by 22.1% in the third quarter. Dimensional Fund Advisors LP now owns 19,975 shares of the company’s stock valued at $110,000 after acquiring an additional 3,615 shares during the last quarter. Finally, DNB Asset Management AS increased its position in Vicarious Surgical by 12.1% in the second quarter. DNB Asset Management AS now owns 29,199 shares of the company’s stock worth $219,000 after purchasing an additional 3,154 shares during the period. Institutional investors and hedge funds own 47.27% of the company’s stock.

Vicarious Surgical Company Profile

Vicarious Surgical develops a next-generation robotic surgical system that integrates virtual reality (VR) with minimally invasive instrumentation. Its flagship offering combines ultra-slender, articulated robotic arms with a VR surgeon console, allowing physicians to perform laparoscopic procedures with enhanced precision, dexterity and visual immersion. The platform is designed to reduce patient trauma compared with traditional open or laparoscopic surgery and to expand surgeon access to challenging operative sites.

The company’s technology is intended for use across multiple surgical specialties, including general surgery, gynecology and urology.